Mount Yale Investment Advisors LLC Invests $259,000 in Insmed Incorporated (NASDAQ:INSM)

Mount Yale Investment Advisors LLC purchased a new stake in shares of Insmed Incorporated (NASDAQ:INSM) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,552 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

Other large investors have also recently bought and sold shares of the company. Darwin Global Management Ltd. purchased a new position in Insmed during the 2nd quarter valued at about $237,076,000. Capital International Investors purchased a new position in Insmed during the first quarter valued at approximately $43,973,000. Clearbridge Investments LLC acquired a new position in Insmed in the 1st quarter valued at approximately $25,242,000. Fiera Capital Corp purchased a new stake in Insmed in the 2nd quarter worth approximately $40,570,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of Insmed during the 2nd quarter valued at $38,056,000.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $70.96 on Monday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market cap of $10.55 billion, a P/E ratio of -13.57 and a beta of 1.11. The business’s 50 day moving average is $73.83 and its two-hundred day moving average is $60.03. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. Insmed’s revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.78) EPS. On average, equities analysts expect that Insmed Incorporated will post -5.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on INSM. Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Thursday, August 29th. JPMorgan Chase & Co. increased their price objective on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Thursday, October 3rd. Finally, UBS Group lifted their target price on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $82.73.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the sale, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,882 shares of company stock worth $5,765,446. Company insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.